MCL1 and cancer: In recent years, it has been learnt that the effectiveness of BAD BH3-mimetics are dependent on the Mcl-1 expression and studies suggest that cancer cells can quickly acquire resistance to ABT-737 by up-regulation of Mcl-1 [24], [33].